Monday, May 29, 2023
HomeAuthorsPosts by Life Sciences Times

Life Sciences Times

52 POSTS0 Comments
Life Sciences

First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States

Life Sciences Times - 0
Life Sciences

CitiusTech Achieves Amazon Web Services Healthcare Competency Partner Status

Life Sciences Times - 0
Life Sciences

KBI Biopharma Expands US Operations with New $150 Million Commercial Manufacturing Facility Based in RTP, North Carolina

Life Sciences Times - 0
Life Sciences

Oxford Finance Closes $60 Million Credit Facility with RxSight

Life Sciences Times - 0
Life Sciences

Singerman Real Estate (SRE) and HATCHspaces®JV expand in Thousand Oaks Purchasing a 50,000 SF +/- cGMP small molecule manufacturing facility from Amgen

Life Sciences Times - 0
Life Sciences

Achieve Life Sciences Announces Proposed Public Offering

Life Sciences Times - 0
Life Sciences

Samsung Introduces Its Latest Radiology Innovations at RSNA 2020

Life Sciences Times - 0
Life Sciences

Agilent Announces Launch of Global Biomarker Pathologist Training Program

Life Sciences Times - 0
Life Sciences

Blackstone Announces Agreement to Acquire DCI, a Pioneer in Technology-driven, Quantitative Credit Investing

Life Sciences Times - 0
Life Sciences

Breakthrough Properties Raises $1 Billion for Life Science Real Estate Investments

Life Sciences Times - 0
123...6Page 1 of 6

TOP AUTHORS

Life Sciences Times
4250 POSTS0 Comments
https://blstimes.com
Life Sciences Times
52 POSTS0 Comments

Most Read

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Contact us: [email protected]

FOLLOW US

© Newspaper WordPress Theme by TagDiv